A new drug targeted at preventing the recurrence of liver cancer after it is treated surgically is expected to receive approval in most Asian countries by 2015, according to the company authorized to develop, produce and market the drug.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Culture
Taiwan, France, Austria launch Indigenous Tao music archive project
07/30/2025 09:48 PM - Cross-Strait
Taiwan decries Chinese coast guard 'harassment' off Kinmen
07/30/2025 09:35 PM - Society
Supreme Court upholds life sentence for man guilty of double homicide
07/30/2025 09:16 PM - Culture
Taiwan brings jazz and dance to George Town Festival
07/30/2025 08:49 PM - Culture
Taiwan National Railway Museum to open after nine years of restoration work
07/30/2025 08:37 PM